Innaxon

Resveratrol Lipodisq™ Sterile Solution

CHF 244.00

In stock

IAX-700-105-L0011 mlCHF 244.00

More Information
Product Details
Synonyms	trans-3,4’,5-Trihydroxystilbene; trans-Resveratrol; (E)-Resveratrol; 3,4’,5-Stilbenetriol
Product Type	Chemical
Properties
Formula	C₁₄H₁₂O₃
MW	228.2
CAS	501-36-0
RTECS	CZ8987000
Purity Chemicals	≥95% (HPLC)
Appearance	Light amber coloured clear aqueous solution
Solubility	Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Reconstitution	Avoid the use of buffers with divalent ions such as Ca or Mg or pH <6.5 or >8.0, which can cause particle instability. Unformulated resveratrol is soluble in DMF or DMSO.
Formulation	Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
Concentration	1mg/ml (0.1% w/vol)
Biological Activity	Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
Declaration	Manufactured by Innaxon.
Other Product Data	Click here for Original Manufacturer Product Datasheet: Our product description may differ slightly from the original manufacturers product datasheet. Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
InChi Key	LUKBXSAWLPMMSZ-OWOJBTEDSA-N
Smiles	OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Keep sterile. Avoid skin and eye contact.
Use/Stability	Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Resveratrol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution.
Potent phenolic antioxidant found in grapes and red wine. Eicosanoid synthesis and platelet aggregation inhibitor. Chemopreventive. Specific inhibitor of cyclooxygenase-1 (COX-1). Anti-inflammatory, anticancer and antiproliferative compound. Apoptosis and autophagy inducer. Potent SIRT1 (sirtuin 1) activator. Senescence modulator. Cardioprotective and neuroprotective. Adipogenesis inhibitor.
Resveratrol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.

Product References

Antiviral Activity of Resveratrol against Human and Animal Viruses: Y. Abba, et al.; Adv. Virol. 2015, 184241 (2015)
Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19? G.A. Rossi, et al.; Front. Immunol. 12, 670955 (2021)
Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability: N. Gligorijevic, et al.; Molecules 26, 2834 (2021)
Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air–Liquid Interface Cultured Human Primary Bronchial Epithelial Cells: B.M. Ter Ellen, et al.; Viruses 13, 1335 (2021)
COVID-19: immunopathology, pathophysiological mechanisms, and treatment options: L.E. Van Eijk, et al.; J. Pathol. 254, 307 (2021)
Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates: S. Fakhri, et al.; 26, 2917 Molecules (2021)
Bioactivity, bioavailability, and gut microbiota transformations of dietary phenolic compounds: implications for COVID-19: P.R. Augusti, et al.; J. Nutr. Biochem. 97, 108787 (2021)
Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients: M.-T. Liao, et al.; Antioxidants 10, 1440 (2021)
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor: M. Oz, et al.; Pharmacol. Ther. 221, 107750 (2021)
Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention: N. Gligorijevic, et al.; Int. J. Mol. Sci. 22, 12385 (2021)
Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders: R. Giordo, et al.; Molecules 26, 856 (2021)
The Importance of Nutraceuticals in COVID-19: What’s the Role of Resveratrol? E. Domi, et al.; Molecules 27, 2376 (2022)
COVID-19: Immunology, Immunopathogenesis and Potential Therapies: A. Bhardwaj, et al.; Int. Rev. Immunol. 41, 171 (2022)

General References for Lipodisq™ Technology:

Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001)
Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012)
Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020)
Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022)
Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)

Call	+41 61 926 6040
Fax	+41 61 926 6049